Skip to content
etf.net

OZEM

GradeCNASDAQ Global Market

Roundhill Investments - GLP-1 & Weight Loss ETF

Themes · Roundhill Investments · Inception 2024-05-21

$31.80−0.36 (−1.12%)

As of Sep 23, 2026, 2:07 PM EDT

History starts May 21, 2024.
Intraday session: down, 34 prints from 32.16 to 31.80. Range 31.66 to 32.16. Use the arrow keys to read each point.$32.00$32.2010 AM12 PM2 PM4 PM
Expense ratio
0.59%
Fund size
$60M
1Y return
+17.9%
Yield · Last 12 months
1.27%
Holdings
29
Volume · 30D
0M sh
NAV per share
$32.11
52W range
low $26.34high $37.15

The ETF.net OZEM Grade

C

44/ 100

Rank 7 of 9 in Pharma & Therapeutics⁠

Confidence Medium

Six-pillar profile for OZEM. Scores out of 100: Cost 41, Risk 22, Mission 68, Tradability 27, Holdings 59, Durability 42. Strongest: Mission (68). Weakest: Risk (22). Leans toward Mission.
F< 25
D≥ 25
C≥ 40
B≥ 55
A≥ 70

Score 44 of 100 sits in the C band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.

  • Cost

    What you pay to own it — the expense ratio plus trading frictions, ranked within its category.
    CScore 41
    Category rank5/9 · mid-pack

  • Mission

    How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.
    BScore 68
    Category rank4/6 · mid-pack

  • Risk

    How violently it can move — volatility, drawdown depth, and downside capture versus its category.
    FScore 22
    Category rank8/9 · bottom quartile

  • Tradability

    How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.
    DScore 27
    Category rank7/9 · bottom quartile

  • Holdings

    What it actually owns — the quality, breadth, and concentration of the underlying portfolio.
    BScore 59
    Category rank5/9 · mid-pack

  • Durability

    Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.
    CScore 42
    Category rank7/9 · bottom quartile

Graded as of Sep 22, 2026

Our read on OZEM

ETF.net Research

CThe whole weight-loss trade in one ticker: roughly 30 stocks covering the drugmakers behind GLP-1 treatments plus the companies expected to benefit as use widens. Broad pharma funds bury this theme. OZEM is built entirely around it.

Stated mandate

The Fund seeks capital appreciation by providing exposure to companies developing pharmaceutical drugs for weight loss and anti-obesity, including GLP-1 treatments, as well as companies expected to benefit from their wider use.

Why people hold it

  1. 01The mandate is explicit: companies developing weight-loss and anti-obesity drugs, including GLP-1s, plus firms expected to benefit from wider use. No hedging into general pharma.
  2. 02A roughly 30-stock lineup means the theme actually drives the fund, rather than sitting as a small sleeve inside a diversified pharma basket.
  3. 03At 0.59%, the fee sits in the same neighborhood as established pharma funds like PJP (0.57%) and FTXH (0.60%), despite the narrower, more specialized mandate.

Worth knowing

  1. 01Broad pharma alternatives are cheaper: XPH at 0.35% and PPH at 0.36%. The theme focus here carries a price.
  2. 02Thinly traded with a modest asset base, so spreads can be wide. Limit orders are the standard tool for funds in this range.
  3. 03Launched in 2024, so the history is short, and a 30-stock single-theme basket swings on trial results and regulatory news at a handful of companies.

OZEM Holdings

As of Sep 20, 2026, 5:42 AM
Asset class
Stocks
Holdings
29
Top-10 weight
66%
Largest holding
NVO12.5%

Sectors

Geography

The fund’s holdings, weight-ordered — page 1 of 2.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001NVONovo Nordisk A/S12.46%168,720$7M35
002LLYEli Lilly & Co12.45%6,323$7M569
003PFEPfizer Inc7.34%155,443$4M374
004KLRAKailera Therapeutics Inc5.71%260,799$3M51
0051093.HKCSPC Pharmaceutical Group Ltd5.69%2,930,000$3M81
0064519.TChugai Pharmaceutical Co Ltd4.94%67,500$3M136
007VKTXViking Therapeutics Inc4.79%96,697$3M94
0081672.HKAscletis Pharma Inc4.64%2,375,000$3M23
009128940.KSHanmi Pharm Co Ltd4.20%6,768$2M43
010ZEAL.COZealand Pharma A/S4.07%55,165$2M56
011AMGNAmgen Inc3.93%5,971$2M470
012AZNAstraZeneca PLC3.83%13,509$2M68
013ROP.SWRoche Holding AG3.17%4,286$2M196
0143933.HKUnited Laboratories International Holdings Ltd/The2.83%1,644,000$2M51
015GPCRStructure Therapeutics Inc2.72%45,508$2M19

Showing 1–15 of 25 holdings

OZEM Performance

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

OZEM$11,786
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,723
Sep 22, 2025 to Sep 22, 2026. OZEM $11,786. SPY $11,723. Use the arrow keys to read each point.$9,209$11,548$13,887Sep 2025Mar 2026Sep 2026

Sep 22, 2025 – Sep 22, 2026

Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for OZEM. Periods over one year show the average yearly return.
PeriodOZEM
Year to date−5.9%
1 month−4.9%
3 months+3.7%
1 year+17.9%
3 yearsFund is under 3 years old—per year
5 yearsFund is under 5 years old—per year
10 yearsFund is under 10 years old—per year

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for OZEM
YearReturn barOZEM
2026 YTD−5.9%
2025+41.9%
2024−3.8%

Since listing, May 21, 2024

OZEM in the news

ETF.net Research hasn’t filed on OZEM yet — coverage lands here as it’s written.

OZEM Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Sep 22, 2026.
1.27%Last 12 months
Payout per share
$0.41Last 12 months
Last payment
$0.41 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Irregular

Distribution history

2024–2026

One bar per payment. 2 payments from 2024 to 2026 YTD. Dec 30, 2024 $0.05; Dec 30, 2025 $0.41. Use the arrow keys to read each point.202420252026YTD
Ex-datePay dateAmount per share
Dec 30, 2025Dec 31, 2025$0.41
Dec 30, 2024Dec 31, 2024$0.05

OZEM Risk

How much the fund’s monthly returns vary, scaled to a year.
19.9%
Annualised · 27 months to Aug 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.53
vs 3-month T-bills · 27 months to Aug 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−28.6%
28 months · trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.43
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

OZEM Cost

Expense ratio0.59%
  • The middle half of Pharma & Therapeutics funds
  • Median 0.58%

5 of the 9 Pharma & Therapeutics funds charge less.

OZEM costs $59.00 a year on $10,000. The median Pharma & Therapeutics fund costs $58.00.